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ABSTRACT
Introduction: Enterobacteriaceae strains are a leading cause of bloodstream infections (BSI). The aim of this study is to assess 
differences in clinical outcomes of patients with BSI caused by Enterobacteriaceae strains before and after introduction of an 
automated microbiologic system by the microbiology laboratory. Methods: We conducted a retrospective cohort study aimed to 
evaluate the impact of the introduction of an automated microbiologic system (Phoenix™ automated microbiology system, Becton, 
Dickinson and Company (BD) - Diagnostic Systems, Sparks, MD, USA) on the outcomes of BSIs caused by Enterobacteriaceae 
strains. The study was undertaken at Hospital São Paulo, a 750-bed teaching hospital in São Paulo, Brazil. Patients with BSI 
caused by Enterobacteriaceae strains before the introduction of the automated system were compared with patients with BSI 
caused by the same pathogens after the introduction of the automated system with regard to treatment adequacy, clinical cure/
improvement and 14- and 28-day mortality rates. Results: We evaluated 90 and 106 patients in the non-automated and automated 
testing periods, respectively. The most prevalent species in both periods were Klebsiella spp. and Proteus spp. Clinical cure/
improvement occurred in 70% and 67.9% in non-automated and automated period, respectively (p=0.75). 14-day mortality rates 
were 22.2% and 30% (p=0.94) and 28-day mortality rates were 24.5% and 40.5% (p= 0.12). There were no significant differences 
between the two testing periods with regard to treatment adequacy, clinical cure/improvement and 14- and 28-day mortality rates. 
Conclusions: Introduction of the BD Phoenix™ automated microbiology system did not impact the clinical outcomes of BSIs 
caused by Enterobacteriaceae strains in our setting.
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The Enterobacteriaceae family causes a significant number 
of bloodstream infections (BSIs) worldwide. The gradual 
emergence of antimicrobial resistance has led to difficulties in 
treating these infections1,2.
It has been well documented that rapid and reliable blood 
culture results can significantly influence patient’s treatment 
and reduce hospital costs3,4. Over the past 20 years, a variety of 
automated systems have been developed. Several factors have 
favored the use of these systems in microbiology laboratories, 
including reproducibility, ability to track results, reduction in 
contamination, automatic connection to computer lab software 
and opportunity for clinicians to obtain partial and final results 
more quickly5. An additional advantage is to be able to perform 
minimum inhibitory concentration (MIC) tests. However, 
as far as we know, there are no previous studies addressing 
METHODS
Study design
This retrospective cohort study was conducted at Hospital 
São Paulo, a 750-bed university-affiliated hospital located in 
São Paulo, Brazil. The data recorded by the antimicrobial 
management team were used to identify patients hospitalized 
with BSI caused by Enterobacteriaceae strains between August 
2006 and July 2009. The inclusion criteria were: patients 
≥ 18 years and first episode of bacteremia. BSI episode was 
defined by the presence of Enterobacteriaceae strains cultured 
from one or more blood culture plus the following signs or 
symptoms: fever (>380C), chills, or hypotension. Central line 
associated bloodstream infection (CLABSI) follows the same 
criteria but the microorganism cultured from blood was not 
related to an infection at another site. Briefly, the patients were 
divided into two periods: the non-automated and the automated 
the impact of an introduction of automated microbiologic 
systems on outcomes of Enterobacteriaceae infections.
This study was conducted to assess the impact of the 
introduction of an automated microbiologic system on 
the clinical outcomes of bloodstream infections caused by 
Enterobacteriaceae strains among hospitalized patients.
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RESULTS
period. The non-automated period included the BSI episodes 
that occurred from August 2006 to July 2007. In this period, 
bacterial identification and antimicrobial susceptibility testing 
were performed using conventional biochemical tests and disk 
diffusion method, respectively. Conversely, in the automated 
period, from August 2008 to July 2009, the blood cultures were 
analyzed by the BD Phoenix™ automated microbiology system 
(Becton, Dickinson and Company (BD) - Diagnostic Systems, 
Sparks, MD, USA).
We did not include episodes of BSI occurred from 
August 2007 to July 2008 in the study because the automated 
microbiology system was not fully operational. We also 
excluded patients whose medical records could not be located, 
patients with community-acquired infections, patients who were 
not treated with antimicrobials and patients who died within 48 
hours of the BSI diagnosis.
Variables and definitions
The analyzed variables included sex, age, severity scores, 
e.g. acute physiology and chronic health evaluation (APACHE) 
II score and McCabe score, comorbidities, neutropenia, use of 
immunosuppressive agents (e.g. corticosteroids, antineoplastic 
agents), previous surgery, previous hospitalization,  use of 
antibiotics, exposure to invasive procedures (e.g. mechanical 
ventilation, central line), septic shock, hospital location 
[intensive care unit (ICU) or ward], length of hospitalization 
stay, Enterobacteriaceae species isolated, presence of extended-
spectrum beta-lactamase (ESBL), presence of carbapenemase, 
polymicrobial infection, antimicrobial therapy, adequacy 
of antimicrobial therapy, change in antibiotic prescription, 
clinical response and 14-and 28-day mortality rates. Only 
antimicrobials used for more than 48 hours were considered. The 
use of antimicrobials was considered adequate if treatment was 
initiated with at least one antimicrobial to which the pathogen 
showed in vitro susceptibility within 48 hours of blood culture 
collection.
Microbiological procedures 
All cultures were processed in the microbiology laboratory 
at Hospital São Paulo using the Bactec 9000 system (Becton 
Dickinson, Cockeysville, MD). 
Until August 2007, bacterial identification and antimicrobial 
susceptibility testing were performed using biochemical 
tests and the disk diffusion method, respectively. After this 
date, bacterial identification and antimicrobial susceptibility 
testing were performed using the BD Phoenix™ automated 
microbiology system.
Statistical analysis
A student's t-test was performed to compare continuous 
variables. Chi-square or Fisher’s exact tests were used to compare 
categorical variables. A p value < 0.05 was considered significant.
A multiple logistic regression technique was applied, and the 
variables that were significant in the univariate analysis were 
incorporated into the analysis. A p value < 0.05 was considered 
significant.
A total of 196 patients were included in the study, 90 patients 
in the non-automated testing period and 106 patients in the 
automated testing period.
The clinical and demographic characteristics of patients are 
shown in Table 1. There was a predominance of male sex in 
both testing periods (54.4% in the non-automated and 61.3% in 
the automated, respectively). The mean age was 59 years in the 
non-automated [standard deviation(SD) ± 16.8 years] and 64 years 
in the automated period (SD ± 15.9 years), respectively.
Table 1 shows the results of the univariate analysis. In the 
automated testing period, the patients had higher APACHE 
II scores (p <0.001), used more immunosuppressive agents 
(p <0.001) and had more central line-associated BSIs 
(p = 0.002).
There was a prevalence of infections caused by Klebsiella 
spp. and Proteus spp. in both testing periods and a reduced 
prevalence of infections caused by Providencia spp. (p = 0.01) 
in the automated testing period. During this same period, we 
observed a higher resistance rate to ciprofloxacin (p = 0.002) and 
piperacillin-tazobactam (p = 0.01) (Table 2). The prevalence 
of ESBL-producing strains was similar in the two periods. 
Klebsiella pneumoniae and Proteus mirabilis were the most 
frequent ESBL-producing pathogens isolated. In the automated 
testing period, Klebsiella pneumoniae carbapenemase (KPC)-
producing was identified in two blood cultures by polymerase 
chain reaction (PCR) method.
The treatment adequacy was similar in both periods 
and the appropriate antimicrobial treatment was initiated in 
80% of episodes within the first 48 hours after infection. In 
approximately one-third of the cases a change in antimicrobial 
therapy was undertaken due to initial antimicrobial resistance. 
The antimicrobial management team recommended changes in 
approximately 40% of the episodes. There was a non-significant 
increase in antimicrobial descalation rate in the automated 
testing period when compared with the non-automated testing 
period (17.6% vs. 28.1%, respectively). There was no difference 
in clinical cure/improvement rates between the two periods. 
The clinical cure/improvement rate were 70% and 67.9% in the 
non-automated and automated period, respectively (p=0.75). 
In addition, no statistically significant difference was observed 
between the two periods with regard to mortality rates. The 14-
day and 28-day mortality rates in the first period were 22.2% 
and 24.5% and they were 30% and 40.5% in the second period 
(Table 3).
All of the statistical analyses were performed using 
Statistical Package for the Social Sciences (SPSS) version 15.0 
(Chicago, IL)
Ethical considerations
The study was approved by the local Ethics Committee, 
number 1149/09.
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TABLE 2 - Etiologic agents and resistance profile of episodes of bloodstream infections caused by Enterobacteriaceae strains. 
 Non-automated Automated  
 period period
 (n = 90) (n = 106) 
 n % n % p
Enterobacteriaceae    
Klebsiella spp. 33 36.6 46 43.3 0.34
Proteus spp. 12 13.3 20 18.8 0.30
Providencia spp. 11 12.2 3 2.8 0.01
Serratia spp. 9 10.0 16 15.0 0.30
Enterobacter spp. 12 13.3 16 15.0 0.73
Escherichia coli 12 13.3 6 5.6 0.06
Morganella morgannii 3 3.3 1 0.9 0.24
Citrobacter spp. 2 2.2 1 0.9 0.47
ESBL 28 31.1 45 42.4 0.10
Escherichia coli 3 10.7 3 6.6 0.83
Klebsiella pneumoniae 20 71.4 32 71.1 0.21
Proteus  mirabilis 5 17.8 10 22.2 0.31
Resistance profile   
ciprofloxacin 28/78 35.8 60/103 58.2 0.002
ceftriaxone 55/88 62.5 40/55 72.7 0.21
cefepime 45/85 52.9 69/106 65 0.09
imipenem-cilastatin 2/89 2.2 2/106 1.8 0.86
meropenem 0/51 0.0 1/62 1.6 0.30
piperacillin-tazobactam 3/86 3.4 42/105 40.0 0.01
ESBL: extended-spectrum beta-lactamase.
TABLE 1 - Demographic and clinical characteristics of bloodstream infections caused by Enterobacteriaceae strains. 
 Non-automated period  Automated period  
 (n= 90) (n= 106)
Variables n % n % OR (CI 95%) p
Male sex 49 54.4 65 61.3 0.75 (0.43 - 1.33) 0.33
Age, mean, SD                                                                                             59.63 ± 16.89                                   64.1 ± 15.9                           - 0.06
McCabe    
nonfatal 41 45.5 42 39.6 1.28 (0.72 - 2.25) 0.40
APACHE II, mean ,SD                                                                                  17.31 ± 6.74                                   20.99 ± 7.57                       -                     <0.001
APACHE II > 15 56 62.2 81 76.4 0.51 (0.27 - 0.94) 0.03
Two or more comorbidities 62 68.8 71 66.9 1.09 (0.6 - 1.99) 0.78
Neutropenia 4 4.4 2 1.8 2.42 (0.43 - 13.52) 0.30
Use of immunosuppressive agents 18 20 49 46.2 0.29 (0.15 - 0.55) <0.001
Prior hospitalization 28 31.1 28 26.4 1.26 (0.68 - 2.34) 0.47
Prior surgery 33 36.6 30 28.3 1.47 (0.8 - 2.68) 0.21
Prior antibiotic use 65 72.2 85 80.1 0.64 (0.33 - 1.25) 0.19
Invasive procedures 77 85.5 91 85.8 0.98 (0.44 - 2.18) 0.95
LOS before BSI, median, SD                                                                        30.98 ± 29.41                                32.55 ± 26.39     - 0.69
ICU admission  at the time of BSI 62 68.8 72 67.9 1.05 (0.57 - 1.91) 0.88
Septic shock 19 21.1 24 22.6 0.91 (0.46 - 1.81) 0.12
Site of infection    
pulmonary 30 68.1 25 62.5 1.62 (0.87 - 3.03) 0.13
urinary tract 8 18.1 10 25 0.94 (0.35 - 2.48) 0.90
intra-abdominal 1 2.2 3 7.5 0.39 (0.04 - 3.77) 0.40
skin/soft tissue 4 9 2 5 2.42(0.43 - 13.52) 0.30
central line 13 14.4 35 33 0.34 (0.17 - 0.7) 0.002
other 21 23.3 15 14.1 1.85 (0.89 - 3.84) 0.10
Polymicrobial infection 15 16.6 16 15 1.13 (0.52 - 2.43) 0.76
SD: standard deviation; APACHE II: acute physiology and chronic health evaluation II; LOS: length of stay; BSI: bloodstream infection; ICU: intensive care unit; OR: odds ratio; CI95%: confidence 
interval 95%.
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The importance of MIC results has been well documented in 
studies of methicillin-resistant Staphylococcus aureus (MRSA)6,7. 
However, there are few published studies demonstrating 
the impact of knowledge of MIC results on the outcomes of 
bloodstream infections caused by Enterobacteriaceae strains. 
Moreover, none of these studies has assessed the effect of the 
introduction of an automated microbiologic testing method on 
the clinical outcome of these infections.
We noticed an increase in ciprofloxacin and piperacillin-
tazobactam resistance during the automated testing period.
These results could be explained by the increased number 
of ESBL-producing strains, which usually are resistant to 
fluoroquinolones as well. Accordingly, a non-significant increase 
in the resistance to third- and fourth-generation cephalosporins 
was observed among those strains.
We observed higher MIC
50
 and MIC
90
 values to cefepime, 
ceftazidime and piperacillin-tazobactam among Klebsiella spp. 
strains. The MIC values determined in our study are higher 
than those described in the SENTRY antimicrobial surveillance 
program with Brazilian hospitals data8. In that study, the MIC
50
 
values for cefepime, ceftazidime and piperacillin-tazobactam 
among Klebsiella strains (n=735) were 0.25, ≤ 1 and 4, 
respectively. Indeed, in our analysis, only imipenem-cilastatin 
demonstrated reasonable activity against Klebsiella strains. 
It is noteworthy that two cases of carbapenemase-producing 
K. pneumoniae were found among these strains.
The analysis of Proteus strains revealed that the MIC
50
 
values for ceftazidime and piperacillin-tazobactam were lower 
than those of Klebsiella strains whereas the MIC
50
 values for 
cefepime and ciprofloxacin were similar. Despite the higher 
MIC
50
 and MIC
90
 of Proteus spp., their susceptibility to 
imipenem was 100%. These data highlight the high rates of 
antimicrobial resistance among Enterobacteriaceae strains in 
our setting.
Studies conducted in recent years have demonstrated that the 
inappropriate use of antibiotics is high9. Proper administration of 
antimicrobial drugs involves the appropriate use of antibiotics 
based on adequate selection of the dose, duration and route 
of administration. This strategy would minimize toxicity, 
costs related to treatment and limit the potential emergence of 
antibiotic resistant strains9,11-14.
We found an eighty percent of treatment adequacy in both 
periods. This favorable adequacy rate is likely due to the use 
of broad-spectrum antibiotics at the beginning of treatment 
probably owing to the high levels of antimicrobial resistance 
rates in our hospital.
Antibiotic changes occurred at the same rate in both periods. 
These changes were recommended in less than 50% of the episodes by 
the antimicrobial management team. Indeed, there was no difference 
in antimicrobial switching rates by the antimicrobial management 
group after the introduction of the automated testing method 
(37.7% vs. 30.1%, p=0.26). 
We found a non-significant increase in antimicrobial 
descalation rate (17.6% vs. 28.1%) after the introduction of the 
automated system. It would be interesting to observe whether 
this trend will continue in future analyses. Antimicrobial 
descalation after microbiological results is a key component in 
reducing antimicrobial resistance rates caused by the selective 
pressure of broad-spectrum antimicrobial therapy10,15.
Despite the high treatment adequacy, the 14-day mortality 
was almost 25% in both periods. However, it is difficult to 
distinguish the outcomes associated with infection from those 
related to the severity of illness among those patients16,17.
Unlike published reports for gram-positive bacteria 
(e.g. MRSA), the knowledge of MIC results did not have 
impact on mortality rates in our study6,7. Probably, the assistant 
physician is aware of the high level of antimicrobial resistance 
in our setting resulting in the prescription of broad-spectrum 
empirical antimicrobial treatments. Thus, as usually carbapenem 
antibiotics have been largely used, the knowledge of MIC results 
would have a lesser impact on outcomes in the automated period.
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TABLE 3 - Variables associated with clinical outcomes of episodes of bloodstream infection caused by Enterobacteriaceae strains.
 Non-automated period  Automated period  
 (n= 90) (n= 106)
Variables n % n % OR (CI 95%) p
Treatment adequacy 72 80.0 80 75.4 1.21 (0.62 - 2.38) 0.45
Antibiotic change 34 37.7 32 30.1 1.4 (0.77 - 2.54) 0.26
Reason     
antimicrobial resistance 18/34 52.9 12/32 37.5 1.88 (0.7 - 5.01) 0.21
lack of clinical improvement 8/34 23.5 10/32 31.2 0.68 (0.23 - 2.01) 0.48
antimicrobial descalation 6/34 17.6 9/32 28.1 0.55 (0.17 - 1.77) 0.31
Clinical cure/improvement 63 70.0 72 67.9 1.1 (0.6 - 2.02) 0.75
14th day mortality  20 22.2 26 24.5 0.97 (0.45 - 2.10) 0.94
28th day mortality  27 30.0 43 40.5 0.53 (0.24 - 1.19) 0.12
OR: odds ratio; CI95%: confidence interval 95%.
DISCUSSION
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Our study had several limitations. First, the retrospective 
nature of the study contributed to loss of data including the lack of 
some MIC results during the automated testing period. Secondly, 
we could not analyze the time that the microbiological results 
became available to the attending physician in both testing periods. 
This point is very important because one of the major advantages 
of automated systems is the rapid time around when compared to 
conventional systems. However, according to information from 
the microbiology laboratory team this time has been substantially 
reduced after the automated system introduction. Thirdly, it was 
difficult to distinguish the mortality associated with the BSI 
infection from that caused by the severity of illness. Finally, 
although our study was performed in a large teaching hospital 
our results may not be applicable to other patient populations.
In summary, our study did not demonstrate impact of the 
introduction of an automated microbiologic system on clinical 
outcomes of patients with bloodstream infections caused by 
Enterobacteriaceae strains. Our data draw attention to the high 
rates of antimicrobial resistance among Enterobacteriaceae 
strains in our institution.
